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* Source measurement does not strictly limit responses to pharmaceutical opioids, but instead lists “pain killers,” “pain medicine,” “pain relievers,” or “narcotics other than heroin”
ϯ Scale categorization indicates the highest geographical scale at which the source is relevant. Many sources also have more detailed information at smaller scales than are listed here.
Bold type font indicates a data source that is publicly available. 
Acronyms Used: ACMT (American College of  Medical Toxicology), ARCOS (Automation of  Reports and Consolidated Order System), CDAS (Center for Drug and Alcohol Stud-
ies), DAWN (Drug Abuse Warning Network), MTF (Monitoring the Future), NAVIPPRO (National Addictions Vigilance Intervention and Prevention Program), NESARC 
(National Epidemiologic Survey on Alcohol and Related Conditions), NIS (Nationwide Inpatient Sample), NLAES (National Longitudinal Alcohol Epidemiology Survey), NPDS 
(National Poison Data System), NSDUH (National Survey on Drug Use and Health), NVDRS (National Violent Death Reporting System), NVSS (National Vital Statistics System), 
VA (Veterans Affairs), RADARS® (Researched Abuse, Diversion and Addiction-Related Surveillance), TEDS (Treatment Episode Data Set)
Three tables provide a guide to existing data 
sources regarding the nonmedical use of  
pharmaceutical opioids in the United States. 
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Background
Recent increases in the nonmedical use of  pharmaceutical 
opioids and the adverse outcomes associated with them 
have stimulated a large amount of  research and data collec-
tion on this public health problem. Systematic organization 
of  the available data sources is needed to facilitate ongoing 
research, analysis, and evaluation.
Method
A list of  keywords associated with diversion, nonmedical 
use, and adverse outcomes of  pharmaceutical opioid use 
generated 94 peer-reviewed academic articles and a number 
of  governmental and nongovernmental sources. All sources 
were in English, contained quantitative data, and were pub-
lished between January 1995 and April 2012. A list of  20 
topics was developed independently by two researchers and 
differences were resolved through discussion. Sources were 
examined for relevance to each topic and categorized ac-
cording to the scale which they were collected. 
Results
The configuration of  data indicates the diverse array of  in-
formation currently available on the nonmedical use of  
pharmaceutical opioids in the US. Data appear relatively 
sparse regarding nonmedical polydrug use, availability of  
opioids via the black market, and mechanisms of  opioid di-
version, such as doctor shopping and forgery.
see more at http://www.pdx.edu/sysc/opioid-data-sources
Conclusion
This index serves as a reference for researchers and policy-
makers who seek to further our understanding of  the public 
health problems associated with pharmaceutical opioids and 
ameliorate associated adverse outcomes. Outlining the array 
of  available data provides a global perspective and identifies 
topics that contain more and less quantitative information 
to guide our understanding and inform future research di-
rections for the pharmaceutical opioid system in the US.
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Tables 1-3. Categorization of  Data Sources Regarding Nonmedical Use, Diversion, and Adverse Outcomes
Row headings indicate salient topics within each area, while column headings indicate the highest scale at which the data source is relevant. 
Within a table cell, each item (starting with "□") indicates a data source, followed by informational resources and example analyses for that 
source. Items without an explicit source name indicate lists of  independent studies that have been conducted for a given topic and scale level. 
